Ondine Biomedical Financials
| OBI Stock | 11.25 0.75 6.25% |
Ondine | Select Account or Indicator |
Please note, the presentation of Ondine Biomedical's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Ondine Biomedical's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Ondine Biomedical's management manipulating its earnings.
Ondine Biomedical Stock Summary
Ondine Biomedical competes with Berkshire Hathaway, Samsung Electronics, Samsung Electronics, Samsung Electronics, and Chocoladefabriken. Ondine Biomedical is entity of United Kingdom. It is traded as Stock on LSE exchange.| Foreign Associate | Germany |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | UK Stock View All |
| Exchange | London Exchange |
| ISIN | CA68234M2058 |
| Business Address | 1100 Melville Street, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | ondinebio.com |
| Phone | 604 669 0555 |
You should never invest in Ondine Biomedical without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Ondine Stock, because this is throwing your money away. Analyzing the key information contained in Ondine Biomedical's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Ondine Biomedical Key Financial Ratios
There are many critical financial ratios that Ondine Biomedical's investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Ondine Biomedical reports annually and quarterly.| Revenue | 1.2 M | ||||
| Gross Profit | 981 K | ||||
| EBITDA | (13.79 M) | ||||
| Net Income | (14.41 M) | ||||
| Total Asset | 5.73 M |
Ondine Biomedical Key Balance Sheet Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Total Assets | 2.6M | 34.1M | 16.6M | 5.7M | 6.6M | 9.0M | |
| Net Debt | 30.8M | (29.6M) | (12.2M) | (2.4M) | (2.8M) | (2.7M) | |
| Retained Earnings | (182.1M) | (232.5M) | (251.9M) | (266.3M) | (239.7M) | (227.7M) | |
| Accounts Payable | 237K | 1.2M | 388K | 1.4M | 1.6M | 923.0K | |
| Cash | 626K | 30.4M | 13.1M | 3.0M | 3.4M | 4.5M | |
| Net Receivables | 543K | 248K | 133K | 220K | 198K | 269.6K | |
| Total Liab | 36.5M | 4.5M | 4.9M | 3.6M | 4.2M | 4.0M | |
| Total Current Assets | 1.7M | 33.5M | 15.1M | 4.8M | 5.5M | 7.7M | |
| Other Current Liab | 4.2M | 2.1M | 3.2M | 1.7M | 2.0M | 1.0M | |
| Other Current Assets | 717K | 2.1M | 710K | 703K | 632.7K | 1.1M | |
| Short Term Debt | 31.4M | 645K | 359K | 382K | 439.3K | 417.3K | |
| Inventory | 404K | 1.1M | 1.3M | 1.1M | 1.2M | 646.2K | |
| Net Invested Capital | 334K | 30.2M | 11.6M | 2.1M | 2.4M | 2.3M | |
| Net Working Capital | (34.0M) | 29.6M | 11.2M | 1.3M | 1.4M | 1.5M |
Ondine Biomedical Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Operating Income | (15.9M) | (17.5M) | (18.8M) | (14.8M) | (13.3M) | (14.0M) | |
| Ebitda | (14.6M) | (16.8M) | (18.8M) | (13.8M) | (12.4M) | (13.0M) | |
| Net Income | (16.9M) | (82.8M) | (20.8M) | (14.4M) | (13.0M) | (13.6M) | |
| Income Tax Expense | 710K | 32.7M | 1.4M | 94K | 108.1K | 102.7K | |
| Interest Expense | 491K | 1.2M | 30K | 38K | 34.2K | 32.5K | |
| Ebit | (15.8M) | (17.4M) | (19.3M) | (14.4M) | (12.9M) | (13.6M) | |
| Income Before Tax | (16.2M) | (50.1M) | (19.4M) | (14.4M) | (13.0M) | (13.6M) | |
| Total Revenue | 1.8M | 2.6M | 638K | 1.2M | 1.1M | 943.3K | |
| Gross Profit | 649K | 1.3M | 287K | 703K | 632.7K | 443.9K | |
| Cost Of Revenue | 1.1M | 1.3M | 351K | 500K | 450K | 499.4K | |
| Research Development | 3.3M | 5.0M | 6.3M | 5.1M | 5.9M | 4.5M | |
| Net Interest Income | (491K) | (1.2M) | 161K | 204K | 183.6K | 192.8K |
Ondine Biomedical Key Cash Accounts
Cash flow analysis captures how much money flows into and out of Ondine Biomedical. It measures of how well Ondine is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Ondine Biomedical brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Ondine had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Ondine Biomedical has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 320K | 29.2M | (16.6M) | (10.1M) | (9.1M) | (8.7M) | |
| Free Cash Flow | (6.4M) | (12.6M) | (16.7M) | (13.8M) | (12.4M) | (11.8M) | |
| Capital Expenditures | 99K | 77K | 311K | 177K | 203.6K | 216.4K | |
| Net Income | (16.3M) | (50.1M) | (19.4M) | (14.4M) | (13.0M) | (13.6M) | |
| End Period Cash Flow | 626K | 29.9M | 13.3M | 3.1M | 3.6M | 4.5M | |
| Other Non Cash Items | 832K | 1.4M | 987K | (170K) | (153K) | (145.4K) | |
| Change To Inventory | 86K | (673K) | (337K) | 104K | 93.6K | 98.3K | |
| Depreciation | 1.2M | 514K | 493K | 587K | 675.1K | 571.0K | |
| Investments | 2.9M | (77K) | (311K) | (177K) | (159.3K) | (151.3K) |
Ondine Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Ondine Biomedical's current stock value. Our valuation model uses many indicators to compare Ondine Biomedical value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Ondine Biomedical competition to find correlations between indicators driving Ondine Biomedical's intrinsic value. More Info.Ondine Biomedical is rated below average in return on equity category among its peers. It is considered to be number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Ondine Biomedical's earnings, one of the primary drivers of an investment's value.Ondine Biomedical Systematic Risk
Ondine Biomedical's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Ondine Biomedical volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Ondine Biomedical correlated with the market. If Beta is less than 0 Ondine Biomedical generally moves in the opposite direction as compared to the market. If Ondine Biomedical Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Ondine Biomedical is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Ondine Biomedical is generally in the same direction as the market. If Beta > 1 Ondine Biomedical moves generally in the same direction as, but more than the movement of the benchmark.
Ondine Biomedical Total Assets Over Time
Ondine Biomedical Thematic Clasifications
Ondine Biomedical is part of Drugs investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Drug manufacturing and delivery. Companies involved in medical and pharmaceutical drug research, manufacturing, and delivery
This theme covers Drug manufacturing and delivery. Companies involved in medical and pharmaceutical drug research, manufacturing, and delivery. Get More Thematic Ideas
| Drugs | View |
Ondine Biomedical February 26, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Ondine Biomedical help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Ondine Biomedical. We use our internally-developed statistical techniques to arrive at the intrinsic value of Ondine Biomedical based on widely used predictive technical indicators. In general, we focus on analyzing Ondine Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Ondine Biomedical's daily price indicators and compare them against related drivers.
| Downside Deviation | 4.59 | |||
| Information Ratio | 0.1335 | |||
| Maximum Drawdown | 30.12 | |||
| Value At Risk | (5.88) | |||
| Potential Upside | 6.4 |
Complementary Tools for Ondine Stock analysis
When running Ondine Biomedical's price analysis, check to measure Ondine Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ondine Biomedical is operating at the current time. Most of Ondine Biomedical's value examination focuses on studying past and present price action to predict the probability of Ondine Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ondine Biomedical's price. Additionally, you may evaluate how the addition of Ondine Biomedical to your portfolios can decrease your overall portfolio volatility.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Stocks Directory Find actively traded stocks across global markets | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |